Stockscreener 앱 받기
38.60
27.96%
-14.99
시장 영업 전:
39.60
0.995
+2.58%
전일 마감가:
$53.59
열려 있는:
$44.65
하루 거래량:
3.94M
Relative Volume:
6.56
시가총액:
$1.43B
수익:
$154.15M
순이익/손실:
$-33.58M
주가수익비율:
-40.21
EPS:
-0.96
순현금흐름:
$-20.74M
1주 성능:
-26.86%
1개월 성능:
-18.19%
6개월 성능:
+3.39%
1년 성능:
+50.62%
1일 변동 폭
$38.52
$44.68
1주일 범위
$38.52
$54.49
52주 변동 폭
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
38.60 | 1.98B | 154.15M | -33.58M | -20.74M | -0.96 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.08 | 58.26B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.93 | 54.44B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.61 | 48.41B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.28 | 39.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
498.65 | 22.12B | 3.13B | 1.27B | 1.12B | 26.39 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | BTIG Research | Buy |
| 2025-06-10 | 개시 | William Blair | Outperform |
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Nasdaq
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
Harrow Health Posts Record 2025 Results, Sets 2026 Outlook - TipRanks
Harrow: Q4 Earnings Snapshot - Citizen Tribune
Harrow Health Stock Slides After 2026 Outlook Shock - TipRanks
Harrow Inc. (HROW) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Harrow : Q4-2025 Letter to Stockholders - marketscreener.com
Harrow Earnings Review: Q4 Summary - Benzinga
HROW: 2025 revenue surged 36% to $272.3M, net loss narrowed, and branded sales led growth - TradingView
Harrow 10-K: $272.3M Revenue, $(0.14) EPS on improved net loss - TradingView
[10-K] HARROW, INC. Files Annual Report | HROW SEC FilingForm 10-K - Stock Titan
Earnings Flash (HROW) Harrow Posts Q4 EPS $0.17, vs. FactSet Est of $0.37 - marketscreener.com
Harrow (NASDAQ: HROW) lifts 2025 revenue 36% and sets 2026 outlook - Stock Titan
Why Is Eye-Disease-Focused Harrow Stock Falling Today? - Bitget
Earnings Flash (HROW) Harrow, Inc. Reports Q4 Revenue $89.1M, vs. FactSet Est of $90.0M - marketscreener.com
All eyes on Harrow Health earnings amid VEVYE coverage win - Investing.com
Harrow, Inc. $HROW Shares Sold by Royce & Associates LP - MarketBeat
88,855 Shares in Harrow, Inc. $HROW Bought by Lumbard & Kellner LLC - MarketBeat
Harrow: Q4 Financial Overview - Bitget
Harrow, Inc. (HROW): A Bull Case Theory - Yahoo Finance
HROW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Harrow Health (HROW) Set to Announce Q4 Earnings - GuruFocus
A Preview Of Harrow's Earnings - Benzinga
Harrow’s PharmaPack Aims To Reshape Cataract Surgery Prescribing And Access - simplywall.st
Harrow Bets On AI And PharmaPack To Reshape Ophthalmic Distribution - Yahoo Finance
Is It Too Late To Look At Harrow Health (HROW) After Its 1-Year 90% Surge? - simplywall.st
Harrow, Inc. (HROW) Investor Outlook: A Potential 37% Upside in the Eyecare Pharmaceuticals Sector - DirectorsTalk Interviews
Harrow (HROW) Is Up 8.1% After Launching PharmaPack Cash-Pay Ophthalmic Kits For Cataract Surgery - simplywall.st
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
FOMO Trade: Does Harrow Inc have strong EBITDA marginsMarket Volume Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Will Harrow Inc. stock attract more institutional investorsMarket Growth Report & Expert Verified Movement Alerts - mfd.ru
Harrow to Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026 - Quiver Quantitative
Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 - The Manila Times
Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - markets.businessinsider.com
Harrow, Inc. Announces Cash-Pay Direct-To-Prescriber Pharmapack?? Kits - marketscreener.com
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.08%
자본화:
|
볼륨(24시간):